Clinical Trials Directory

Trials / Terminated

TerminatedNCT04296318

COPD Exacerbation Alert System With urinE anaLysis Using the HEADSTART Device

Protocol for COPE-WEL Observational Validation Trial COPD Exacerbation Alert System With urinE anaLysis - Clinical Validation of the Headstart® Test System for Early Detection of Exacerbations in Moderate/Severe COPD Patients

Status
Terminated
Phase
Study type
Observational
Enrollment
86 (actual)
Sponsor
Mologic Ltd · Industry
Sex
All
Age
40 Years
Healthy volunteers

Summary

The Headstart Test system is an in vitro diagnostic test intended for self-testing for the detection of five biomarkers of infection in the urine of patients diagnosed with chronic obstructive pulmonary disease (COPD). Patient urine testing will be conducted daily to establish a patient baseline biomarker profile and provide ongoing monitoring for changes in the biomarker profile. Headstart results will be used as an aid in monitoring and early detection of pulmonary exacerbation.

Detailed description

Patients will be asked to collect and test a daily urine sample using a novel testing system (HeadStart Test system) in addition to answering questions abut their daily COPD symptoms for 6 months. In summary, this study aims to validate a novel non-invasive point of care (near-patient) testing system, to allow people with COPD to detect pulmonary exacerbations by measuring urinary biomarkers. If successful, we hope that this will provide patients with an easy to use device, which will empower patients and their caregivers to treat exacerbations at an earlier stage, with potential health and economic benefits.

Conditions

Timeline

Start date
2019-11-19
Primary completion
2022-02-15
Completion
2022-07-24
First posted
2020-03-05
Last updated
2022-07-28

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04296318. Inclusion in this directory is not an endorsement.